Introducing VEGF-C into the cerebrospinal fluid of mouse models of glioblastoma, researchers noted increased levels of T cell response to the cancerous tumors. When combined with immune system checkpoint inhibitors, the VEGF-C treatment significantly extended the life span of the mice with glioblastoma brain cancer.
Glioblastoma stem cells' circadian clocks ramp up the cells' metabolism, making them stronger, more resistant to treatment, and able to divide and multiply more rapidly. By targeting the stem cells with a small molecule drug, researchers found mice models lived longer and their tumors shrank.
Novel biomarkers for glioblastoma brain cancer have been identified in bodily fluids. The discovery may lead to a new, simple, non-invasive blood test to detect brain cancer in the future.
Genetics and microenvironment influence the frequency of glioblastoma cells. Researchers provide a new blueprint for glioblastoma, integrating the malignant cell programs, cancer cell plasticity, and modulation by genetic drivers. The findings shed light on why this form of cancer is so hard to treat effectively.
PTEN deficiency drives an increased expression of LOX. LOX attracts macrophages which protect gliobastoma brain cancer cells and provide growth factor support for the tumor, a new mouse study reveals.
Combining an antibiotic drug that targets glutamine with the ketogenic diet helps kill glioblastoma cancer cells, reversing symptoms of the disease and improving survivability in mouse models.
Researchers report administering immunotherapy treatment prior to surgery for those with recurring glioblastoma brain cancer is more effective that using the treatment after surgery.